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Correlation between Choline Level and Gd-DTPA 
Enhancement in Patients with Brain Metastases of 
Mammary Carcinoma 
Paul E. Sijens, Pieter van Dijk, Matthijs Oudkerk 
Single voxel 'H double spin-echo MR spectroscopy was used 
to examine 15 cases of brain metastasis of mammary carci- 
noma (18 lesions) in relation to Gd-DTPA enhanced MR imag- 
ing. For lesions larger than 50% of MRS voxel size, there was 
significant correlation between Gd-DTPA-enhanced MRI sig- 
nal and MRS-detected signal of choline (Cho) containing com- 
pounds ( r  = 0.86, P < 0.01; n = 8). The observed loss of 
correlation when including the smaller lesions was overcome 
by correcting for partial volume effects (r = 0.69, P < 0.002; 
n = 18). Metastasis spectra showed increased Cho compared 
with control spectra, except for those lesions showing detect- 
able lactate (Lact) signal. The detection of Lact in four of the 
larger lesions coincided with comparatively low levels of crea- 
tine (Cr) and Cho and heterogeneous Gd-DTPA enhancement 
(ring-enhancement). It was concluded that in brain metastases 
of mammary carcinoma Lact represents a product of ischemia 
precedinglduring tissue decay resulting in central necrosis, 
rather than tumor specific metabolism resulting in increased 
glycolysis. 
Key words: brain metastases; Gd-DTPA contrast agent; mag- 
netic resonance imaging; magnetic resonance spectroscopy. 
INTRODUCTION 
Gd-DTPA is the most frequently used contrast agent in 
brain MR imaging (1-3). The T, shortening metal chelate 
distributes primarily in the intravascular, extracellular 
space and quickly passes into the extravascular, intersti- 
tial space (4). Used intravenously it provides contrast 
enhancement in Tl-weighted MR images of intracranial 
lesions associated with an abnormal vascular bed, as is 
the case in metastatic lesions, or breakdown of the blood- 
brain barrier (BBB) as is generally the case in the more 
malignant primary brain tumors (5). Metastatic lesions 
possess non-CNS capillaries similar to their tissues of 
origin, so brain metastases virtually always enhance. The 
use of Gd-DTPA for CNS applications has become routine 
in distinguishing the extent of lesions from peritumor 
edema and in detecting residues, recurrence, and growth 
of primary tumors and metastases (2, 6). However, there 
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has been confusion whether necrotic tissues are specifi- 
cally enhanced with Gd-DTPA (4, 7, 8) or to the contrary 
that the necrotic regions in tumors show up as hypoin- 
tense areas (9, 10). 
Localized 'H MR spectra of normal brain tissue meas- 
ured under suppression of the water signal show the 
resonances of Cho, Cr, and NAA. The Cr peak includes 
both creatine and phosphocreatine signal and there are 
still unanswered questions regarding what compounds 
contribute to the Cho and NAA peaks (11). Brain tumors 
have relatively high Cho levels and reduced NAA levels 
( 12-19). Whereas Cho level generally increases with tu- 
mor size, it cannot be used as a discriminator of tumor 
grade because necrotic high grade tumors have low levels 
of Cho (20). Metabolic heterogeneity of human intracra- 
nial tumors has been shown (18, 20-22). Some authors 
have suggested that Lact is concentrated in necrotic tis- 
sue (13, 16) or peritumoral edema (22) as opposed to 
others who correlated the presence of Lact with increased 
glucose uptake (18). 
'H MRS publications to date have focused on the larger 
brain lesions such as (high grade) primary brain tumors. 
Brain metastases are generally small and therefore more 
difficult to characterize by MRS. Single volume MRS was 
used in this study because of the better quality lesion 
spectra obtained after shimming on small volumes com- 
pared with the results of spectroscopic imaging methods, 
which require shimming on larger volumes to obtain ar- 
rays of spectra including the lesion. To our knowledge 'H 
MRS studies including more than a single case of mam- 
mary carcinoma brain metastasis have not been pub- 
lished. New in this study is also the correlation of the 'H 
MRS measured metabolic profiles of brain lesions with 
Gd-DTPA-enhanced MR imaging. 
MATERIALS AND METHODS 
Fifteen patients with untreated brain metastases of mam- 
mary carcinoma, all showing Gd-DTPA-induced signal 
enhancement in Tl-weighted MRI, were examined by 'H 
MRS. MR examinations were performed at 1.5 T using a 
1.512 T sP63/84 Helicon whole-body MR scanner (Sie- 
mens AG, Erlangen, Germany). The standard circular po- 
larized transmitlreceive head coil and 10 mT/m gradient 
system were used for both MRI and MRS. 
Gd-DTPA Enhanced MR Imaging 
MRI studies, preceding the MRS by up to 2 weeks, were 
performed with a Tl-weighted sequence (TRITE 600115, 
2 NEX, matrix size 192 X 256, 314 rectangular FOV) and 
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a T,-weighted sequence (TR/TE 2000/12-80), 1 NEX, ma- 
trix size 192 X 256, 3/4 rectangular FOV) in 6-mm slices. 
TI-weighted MRI was repeated 5 min after administration 
of Gd-diethylenetriamine pentaacetic acid-dimeglumine 
(0.2 mmol Gd-DTPA/kg; Schering AG, Berlin, Germany). 
Brain metastases do not show significant (further) en- 
hancement at later times post-Gd-DTPA contrast (P. van 
Dijk and M. Oudkerk, works in progress). Routines pro- 
vided by the manufacturer of the MR system were used to 
determine the mean signal intensities and standard de- 
viations for the largest transverse 6-mm thickness MRI 
cross section of each lesion. 
Localized 'H MR Spectroscopy 
The use of stimulated echo (STEAM) spectroscopy to 
select a VOI reliably as well as to suppress the unwanted 
water signal in a single experimental step has been de- 
scribed in detail (23). In this study the double spin-echo 
(DSE) sequence rather than the STEAM sequence was 
used because in our experience the gain in signal is close 
to the reported 90% (24). In phantom experiments, arti- 
facts due to acetate or Lact signals from outside the VOI 
were not larger than expected from the calculated chemi- 
cal shift artifacts of 0.074 and 0.037 cm/ppm at the used 
slice selection gradients of 2 mT/m (for selecting volumes 
of 8-36 cm3) and 4 mT/m (for volumes between 1 and 8 
cm3), respectively. Care was taken to ensure proper posi- 
tioning of lesion MRS voxels in those regions that had 
shown signal enhancement in the Gd-DTPA-enhanced 
MRI studies (previous paragraph). Analysis of patient 
spectra was confined to Cho (chemical shift 3.21 ppm), 
Cr (3.02 pprn), NAA (2.01 pprn), and Lact (doublet cen- 
tered at 1.32 ppm with coupling constant of 7 Hz) peak 
integrals. Lipid signals were not quantitated because in 
peripheral voxels contributions from nonspoiled subcu- 
taneous fat signals were often significant. The presented 
MRS data and the spectra shown in the figures were all 
acquired with TE = 135 ms. At TE = 135 ms, due to J 
modulation, the doublet signal of Lact is inverted (180" 
out of phase) relative to the singlets of Cho, Cr, and NAA 
(25). To confirm the identity of presumed Lact peaks, 
MRS measurements were repeated with TE = 270 ms 
(Lact doublet in phase). The whole procedure including 
sagittal and transverse MRI, global shimming, volume 
selection, local shimming, water suppression optimiza- 
tion and the measurement of two voxels took 60 min. The 
acquisition of a sagittal localizer was followed by proton 
density and T,-weighted imaging (1500/12-80) using a 
55" flip angle, 15 slices of 6 mm without a slice gap, a 
128 X 256 matrix and 1 acquisition (3.15 min). The field 
homogeneity achieved in global and local shimming re- 
sulted in water peak line widths of at most 17 Hz and 6 
Hz, respectively. SE MR spectra were collected with 
2.56-ms sinc-shaped RF pulses preceded by 25.6 ms 
Gaussian-shaped RF pulses for chemical shift selective 
excitation (CHESS) and subsequent spoiling of the result- 
ant water signal. The second half of the spin echo was 
collected using 1024 data points and a spectral width of 
500 Hz. All DSE measurements of voxels that varied in 
size between 1 and 36 cm3, were the sum of 256 acqui- 
sitions with four prescans and TR = 1600 ms (acquisition 
time 6.57 min). Typically time domain data were zero- 
filled to 4096 points, multiplied with a Gaussian function 
Ccenter 0 ms, half width 256 ms), Fourier transformed, 
phase corrected and fitted to Lorentzian curves. Because 
the-gradient-induced artifacts in amplitude and phase of 
the l'crealized RF pulses were minor, the spectra were 
already of good quality when not corrected for the effects 
of eddy currents. All MRS data were therefore processed 
without introducing an additional source of error in the 
form of eddy current compensation. 
A pilot study on six healthy volunteers (aged between 
22 and 41 years) demonstrated a fairly constant ratio 
between the total metabolite signals detected in the oc- 
cipital lobe (8 cm3 voxel) and in caput nuclei caudati 
(also 8 cm3), that is 1.09 +- 0.29 SD. To get semiquantita- 
tive data, metabolite levels have been presented as per- 
centages of the NAA level measured in the contralateral 
occipital voxel. The same normalizations were made by 
others (14, 26). Ratios of Cho to NAA and Cr to NAA of 
38 2 6 and 51 ? 13 (percentages 2 SD; occipital lobe) 
and 52 2 10 and 47 +- 10 (corpus nuclei caudati) in the 
healthy volunteer study, confirmed the good reproduc- 
ibility of the MR spectra. Lesion voxels and occipital 
control voxels had the same dimensions, except for le- 
sion voxels larger than 8 cm3 (the largest cubic volume 
not exceeding the dimensions of the occipital lobes of the 
brain). In the latter case differences in voxel size were 
accounted for by normalization. 
Statistics 
Correlation analyses were applied and Student's t test, 
two-tailed, was used in the assessment of the signifi- 
cances of the presented linear correlations and of differ- 
ences between group means. 
RESULTS 
The 'H MRS characteristics of the examined metastases 
of mammary carcinoma are summarized in Table 1. Voxels 
varying in size between 1 and 36 cm3 were selected to in- 
clude the whole abnormality. With respect to their TI- 
weighted MRI behavior on addition of Gd-DTPA, lesions 
could be divided in two categories: (1) more or less ho- 
mogeneously enhancing (Cases 1,  2, 3b, 4-9, 11-13, 15) 
and (2) ring-enhancing, that is nonenhancing areas sur- 
rounded by an enhancing shell (Cases 3a, 10,14). In Table 
1 lesion contrast is presented as percent difference be- 
tween mean lesion signal and normal tissue signal at the 
largest MRI cross section (6-mm slice thickness), and le- 
sion heterogeneity by the included standard deviations. 
There was a significant linear correlation between total 
lesion volume as estimated from postcontrast MRI series, 
and signal heterogeneity (r = 0.59, P < 0.02; n = 18). 
MRS detected metabolite levels are presented in Table 
1 as percentages of the integrated NAA signal in the con- 
tralateral occipital voxel measured in the same patient 
examination. Lesion-containing voxels generally re- 
vealed high Cho, normal Cr, and reduced NAA levels 
compared with the control voxels, which had Cho to 
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Table 1 
Gd-DTPA Enhancement and ’H M R  Spectroscopy Measured Metabolite Levels in Brain Metastases of Mammary Carcinoma 
Lesion Lesion metabolite levels 
divided by filling factor‘ 
MRS detected 
MRS metabolite metabolite Gd-DTPA enhancement MRI vOxel 
size levelsd levelse Lipids Case “yzp (Cm3) Cho Cr NAA Lact Cho Cr Lact Cho Cr Lact Lesion volume ( ~ m ~ ) ~  
1 
2 
3 a  
b 
4 a  
b 
5 
6 
7 
8 
9 
10 
11 
12 
13 a 
b 
14 
15 
6.2 
1.3 
7 
1.1 
12 
0.4 
0.07 
2.6 
3.1 
4.2 
3.6 
1.4 
8.6 
5.0 
12 
1 gh 
22 
0.3 
25 2 8 
29 t 6 
2 2 5  
46 t 12 
28 t 9 
82 ? 6 
47 2 12 
96 2 10 
87 t 27 
90 t 26 
26 2 7 
65 ? 18 
71 ? 28 
34 2 17 
17 2 35 
49 2 13 
-13 2 24 
-6 t 51 
8 65 20 
8 73 47 
8 48 25 
3.4 40 28 
18 168 53 
18 129 64 
8 48 59 
27 84 89 
8 66 10 
8 199 19 
8 103 48 
22.5 19 17 
3.4 78 37 
8 97 10 
27 43 67 
8 76 47 
36 55 50 
8’ 53 7 
1 45 49 
18 
75 
33 
42 
68 
112 
67 
100 
0 
25 
74 
29 
17 
10 
34 
53 
48 
10 
58 
0 
0 
61 
0 
0 
0 
0 
0 
0 
0 
0 
15 
0 
35 
0 
0 
37 
72 
0 
56 11 0 
35.5 9.5 0 
31.5 8.5 61 
19 7 0 
134 19 0 
73 8 0 
14.5 25.5 0 
34 39 0 
66 10 0 
186.5 6.5 0 
66 11 0 
4.5 2.5 15 
69.5 28.5 0 
92 5 35 
26 50 0 
49.5 20.5 0 
31 26 37 
48 2 72 
16 20 0 
72 
21 8 
36 
59 
201 
3285 
1657 
353 
170 
355 
147 
8 
169 
115 
82 
79 
51 
48 
53 
14 
58 
10 
22 
29 
360 
291 4 
143 
3 
12 
24 
5 
69 
6 
157 
33 
43 
2 
67 
o +  
0 
70 + 
0 
0 ++ 
0 -  
0 -  
o +  
0 -  
0 ++ 
o +  
28 + 
0 ++ 
44 - 
0 ++ 
0 ++ 
- 
- 
61 - 
72 - 
0 - 
aTotal lesion volume estimated from postcontrast MRI series. 
bLesion contrast, i.e., percent difference between postcontrast lesion signal (at largest MRI cross-section) and the signal of contralateral brain tissue. 
CLesion heterogeneity, standard deviation in postcontrast lesion MRI signal in percentage of contralateral brain tissue signal. 
dNormalized to the NAA level in contralateral occipital voxels (set at 100). 
eCalculated by subtracting the normal brain tissue contributions from the overall ‘H MRS detected signals shown in previous columns 
“‘filling factor,” lesion volume/MRS voxel size. 
gAbsent (-), low (+), high (++). 
’Major part of lesion located extracerebral. 
‘Center of the same lesion. 
NAA and Cr to NAA ratios similar to those encountered 
in healthy volunteers (Cho = 38 t 6 and Cr = 51 ? 13 SD 
relative to NAA = 100). The ‘H MR spectrum of a voxel 
containing a typical brain metastasis of mammary carci- 
noma (Case 2) is shown in Fig. 1. The level of Cho is 
mildly increased, Cr within the normal range and NAA 
slightly decreased; Lact is not detected. The Gd-DTPA- 
enhanced MRI of the same lesion shows a small area of 
comparatively homogeneous signal enhancement. The 
mean MRI signal intensity in the whole enhanced area 
was 610 ? 60 SD arbitrary units (AU) compared with 
472 2 9 AU in contralateral brain tissue. The percent 
difference between both values, 29%, is listed in Table 1 
(“contrast”). Lesion center signal was measured in a cir- 
cular ROI covering half the total area (637 2 28 AU). The 
quotient between the latter standard deviation, not influ- 
enced by the signal drop on the outer rim, and control 
signal was used as measure of lesion heterogeneity: 281 
472 = 0.06 or 6% (Case 2,  Table 1). The results for a large 
brain metastasis showing more heterogeneous Gd-DTPA 
enhancement are shown in Fig. 2 (Case 4a). The level of 
Cho in the voxel containing the metastasis is very high, 
168% of control NAA level. Lact was not detected. The 
third example is a large brain metastasis showing highly 
heterogeneous Gd-DTPA enhancement, “ring-enhance- 
ment,” in TI-weighted MRI (Fig. 3, Case 14). The Cho 
level, 55% of control NAA, is comparatively low and 
Lact signal is present. The ‘H MR spectra of the whole 
lesion and its mostly hypointense center, upscaled with a 
factor of 4.5 to correct for the difference in MRS voxel 
size, are shown in Fig. 3. In the center of the lesion, the 
levels of Cr and NAA are very low and Lact (the inverted 
doublet at about 1.27 and 1.38 ppm) twice as high as in 
the lesion containing voxel. Alanine, reportedly present 
in meningiomas measured under comparable experimen- 
tal conditions (16, 17), was detected in none of the 18 
MRS examined brain metastases of mammary carcinoma. 
Choline and Creatine 
For lesions larger than 50% of the h4RS voxel size (eight 
out of 18) significant correlation was found between (to- 
tal) Cho level and the lesion MRI signal after administra- 
tion of Gd-DTPA (r = 0.86; P < 0.01). Inclusion of smaller 
lesions leads to loss of correlation which may be attrib- 
uted to dilution of results due to higher normal tissue 
contributions. Correlations between Cr level and either 
Gd-DTPA enhancement, lesion size, or Cho level were 
not found. 
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FIG. 1. ’H MR spectrum of 8 cm3 voxel containing medium-sized 
brain metastasis of mammary carcinoma (left side) scaled relative 
to the spectrum of occipital control voxel (right side) and axial 
T,-weighted MR image (SE SOO/lO) showing circular ROI covering 
half the Gd-DTPA enhanced area (Case 2). MRI signal intensity 
(arbitrary units) is shown for an arbitrary trace through the L-parietal 
lesion. Spectral assignments: Cho 3.21, Cr 3.02 and 3.91, and NAA 
2.01 palls per million relative to tetramethylsilane. 
Correcting for Partial Volume Effects 
Partial volume effects, the lesions being smaller than the 
voxels measured by ‘H MRS, obscure the characteriza- 
tion of metastases of mammary carcinoma. Because NAA 
is generally accepted to be localized in neurons (11, 27), 
it is reasonable to assume that brain metastases do not 
contain NAA. When a second assumption is made, that 
the NAA in the spectra comes with normal brain tissue 
Cho and Cr signals in a ratio of 2:1:1 (roughly the pro- 
portions obtained in occipital brain lobe and in corpus 
nuclei caudati of volunteers), the net lesion metabolite 
levels can be calculated: “Lesion Cho” = Cho - */zNAA, 
“Lesion Cr” = Cr - lhNAA, “lesion Lact” = Lact. Post- 
contrast MRI signal is corrected for partial volume effects 
- 
4 . 0  3.0 2 . 0  1.0PPm 
FIG. 2. ’H MR spectrum of 18 cm3 voxel containing large brain 
metastasis of mammary carcinoma (Case 4a) and axial Tl- 
weighted MR image after Gd-DTPA administration (SE SOO/lO) 
showing a profile through the R-temporal lesion. In addition to Cho, 
Cr, and NAA, there are lipid signals at 0.9 and 1.3 ppm. 
by multiplication of the contrast with the filling factor: 
(Lesion volume) 
(MRS voxel size) Filling factor . Contrast = 
(lesion MRI signal - control MRI signal) 
(control MRI signal) 
with control MRI signal set at 100. 
After applying the above corrections on all lesions, a 
significant positive correlation between the lesion Cho 
signal (“Lesion metabolite level = Cho” in Table 1) and 
the postcontrast MRI signal is found. The resulting linear 
regression is shown in Fig. 4 ( r  = 0.69, P < 0.002; n = 18). 
Lesion metabolite signals per unit of MRI visualized le- 
sion volume are shown in the right-most columns of Table 
I, “lesion metabolite level/filling factor.” In the four le- 
sions showing the weakest MRI enhancement (to inten- 
sities of -13% to +17% relative to normal brain tissue), 
the thus calculated Cho levels are not significantly higher 
than contralateral Cho (Cases 3a, 3b, 10, 14). 
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FIG. 3. 'H MR spectra of 36 cm3 voxel containing large brain 
metastasis of mammary carcinoma and of 8 cm3 voxel positioned 
in the largely hypointense center of the same lesion (the latter 
spectrum upscaled by a factor of 4.5) and axial T,-weighted image 
after Gd-DTPA administration (SE 600/10) showing a profile 
through the R-parietal lesion (Case 14). In addition to Cho, Cr, and 
NAA, there are Lact doublets at 1.27 and 1.38 ppm. 
Lactate 
Quantitation of Lact was straightforward in the majority 
of lesions where lipid signals were absent or low (13 out 
of 18). The MR spectra of the other five lesions showed 
intense lipid signals in phase with the Cho, Cr, and NAA 
signals (i.e., Case 4a, Fig. 2) without a trace of inverted 
doublet Lact signal (1.32 ppm) interfering with the com- 
paratively broad -CH,- lipid resonance (1.3 ppm). The 
Lact coupling constant of 7 Hz and the water line width 
of at most 6 Hz achieved in the local shimming of any 
20 O X 0  
0 
I 0 
10 
I I 0  I I I I I I 
-20 -10 0 10 20 30 40 50 60 
Gd-DTPA ENH.' FILLING FACTOR (X) 
FIG. 4. Lesion Cho level plotted against the product of the Gd- 
DTPAenhancing voxel fraction and lesion contrast (Gd-DTPA enh.* 
filling factor (%)). Linear regression analysis: r = 0.69, P c 0.002; 
n = 18). 
metastasis containing voxel (see Materials and Methods 
section), make the possibility of significant amounts of 
Lact not being recognized and confused with lipid signal 
highly unlikely. Compromising of any Lact level listed in 
Table 1, also the zeros in Cases 4a, 8,11,  and 13ab, by the 
presence of lipid is therefore negligible. Lact was de- 
tected in heterogeneously enhancing lesions (Cases 3a, 
10, 12, 14), most of which had comparatively low Cho 
levels (Cases 3a, 10, 14) and very lqw Cr levels (Cases 3a, 
10, 12). 
DISCUSSION 
For lesions larger than 50% of MRS voxel size (8/18), 
there was significant correlation between Gd-DTPA- 
enhanced MRI signal and MRS-detected choline (Cho) 
signal ( r  = 0.86, P < 0.01). The observed loss of correla- 
tion when including the smaller lesions was overcome by 
correcting for partial volume effects ( r  = 0.69, P < 0.002, 
n = 18; Fig. 4). The knowledge that Cho and other me- 
tabolites are not detected in fully necrotic tissue, war- 
rants the conclusion that our data do not support the 
hypothesis that necrotic tissues are specifically en- 
hanced with Gd-DTPA (4, 7,  8), but to the contrary con- 
firm that the necrotic regions in tumors show up as hy- 
pointense areas (9, 10). 
Significant linear correlation between total lesion vol- 
ume, as determined from postcontrast MRI, and signal 
heterogeneity was shown ( r  = 0.59, P < 0.02; n = 18). 
Lact was only observed in large heterogeneously enhanc- 
ing (ring-enhancing) metastases (Cases 3a, 10,12, and 14) 
and with preference for the lesion center (Case 14; Fig. 3). 
This implies that Lact is only present in late stage lesions 
that contain large necrotic regions. The comparatively 
low lesion Cr and Cho levels at that stage are in line with 
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reduced Cho levels in necrotic high-grade gliomas com- 
pared with solid high-grade gliomas (20). We conclude 
that in brain metastases of mammary carcinoma, the can- 
cer cells do not preferentially ferment glucose to Lact, in 
other words the “Warburg effect” (28,29) does not apply. 
The detected Lact is a product of ischemia preceding/ 
during tissue decay and the formation of central necrosis 
and does not reflect tumor-specific metabolism resulting 
in increased glycolysis. 
These results are in agreement with suggestions that 
Lact might be concentrated in necrotic tissue (13,16) and 
contradict a reported correlation of the presence of Lact 
in intracranial tumors with high Cho levels and increased 
glucose uptake (18). In our experience edema is charac- 
terized by normal Cho and Cr levels and NAA reduced by 
up to 50% (compared with normal brain tissue) and, in 
contrast to an assumption published by others (22), by 
absence of Lact signal. The presented lesion metabolite 
signals have not been corrected for the (not easily quan- 
tifiable) amount of edema rather than normal brain tissue 
included in the MRS voxels. In the volume-corrected 
lesion metabolite levels, it has been assumed that the 
whole lesion is visualized with Gd-DTPA-enhanced MRI 
(last columns in Table 1). The unlikely high Cho and Cr 
levels in two of the smallest lesions might be interpreted 
as evidence that early stage brain metastases of mammary 
carcinoma are only partially visualized with Gd-DTPA- 
enhanced h4RI (Cases 4b, 5). 
This study has contributed both to understanding of 
tumor pathophysiology and to the evolving science of 
metabolic fingerprinting of pathophysiological processes 
by MRS. In characterizing metastatic brain tumors, gen- 
erally small lesions when detected for the first time, 
single voxel ‘H MRS is a perfectly feasible method if not 
the method of choice. Only in four out of 18 lesions 
studied, those exceeding 2.5 cm diameter (Cases 4a, 10, 
12, 14), spectroscopic imaging with a volume resolution 
of 1 cm3 would have yielded additional information re- 
garding tumor heterogeneity. 
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